Metrics as of 10/16/2026, 06:58 AM (Berlin time), refresh in progress.
Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from…
1D
-2.0%
1W
-4.1%
1M
-30.2%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
Not enough history for an assessment
PRICE TARGET LOW
US$37.00
CONSENSUS
US$51.75
MEDIAN
US$55.00
PRICE TARGET HIGH
US$60.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 03/09/2026
FREE FLOAT
10.5%
FLOAT SHARES
1,701,762
AVG. DAILY VOLUME (30D)
473,134
Doudna Jennifer A
ORBIMED ADVISORS LLC
GORDON CARL L
GORDON CARL L
AH Bio Fund II, L.P.
Scribe Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Benjamin L. Oakes, the company employs around 89 people.
The IPO was on 24/07/2026; the stock trades on NASDAQ under the ticker SCTX.
1 analysts rate the stock, the consensus is Buy (as of 03/09/2026).
The average price target is US$51.75, ranging from US$37.00 to US$60.00, with a median of US$55.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 02/12/2026.
No, Scribe Therapeutics currently does not pay a dividend.
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
Clicking "Analyze stock" lets five strategies assess Scribe Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.